More sites. Faster activation. Better data.
PAGONA finds, qualifies, and activates cell therapy sites for your clinical program, helps health systems build the capability to deliver cell therapies well, and gives product teams an inside-the-center view of where access breaks down.
Your trial is limited by the sites that can run it.
Cell therapy trials compete for the same small group of experienced academic centers. Those centers are saturated, enrollment is slow, and the patients they see are not the patients who will use your product at scale. Meanwhile, hundreds of community and regional health systems have the oncology volume you need but have never activated a cell therapy protocol. Turning those systems into capable, compliant trial sites is a specialized job. It is the job we do.
From target profile to first patient enrolled.
Site identification and qualification
We map the health systems that fit your protocol: patient population, referral patterns, apheresis and pharmacy capacity, inpatient support, and leadership appetite. Then we assess each one on the ground, so your feasibility decisions rest on verified capability rather than a questionnaire.
Site readiness and capability build
For sites that are close but not ready, we close the gaps: SOPs, training, toxicity management, product handling, data capture, and governance. Your protocol lands at a site that can execute it, and your monitors spend less time on remediation.
Activation and trial operations
Feasibility, budgets and contracts, regulatory submissions, and start-up support that shortens the path from site selection to first patient enrolled. During the trial, we help sites keep enrollment and data quality high.
Operational readiness for approved therapies
After approval, the constraint moves from enrollment to delivery. We help health systems build the product-agnostic operating foundation for cell therapy, reimbursement processes, contracting, workflows, and trained staff, so that patients whose physicians choose an approved cell therapy can receive it close to home. Our work does not promote any product or influence treatment decisions; it makes sites capable of delivering the therapies their clinicians select.
Site and market insight
Aggregated, de-identified insight into how cell therapy is delivered outside academic centers: where capacity exists, what operational barriers sites face, and what community programs need to run a trial well. Useful for clinical operations, medical affairs, and market access planning.
Six steps, one point of contact.
We work as an extension of your clinical operations, medical affairs, or commercial team, with a single point of contact and reporting built around your milestones.
We already know the sites. That is the head start.
We maintain working relationships with a growing network of community and regional health systems that want to participate in cell therapy trials. For each, we have gathered what a sponsor needs to know before feasibility begins: cell therapy capabilities today, inpatient and outpatient capacity, oncology and non-oncology programs, investigator interest, research infrastructure, and realistic activation timelines. When your protocol arrives, we can tell you within days which sites fit and what it would take to activate them, instead of starting outreach from a blank list.
Sites participate because it gives them one organized channel to trial opportunities and one set of questions to answer rather than ten. Sponsors engage because it collapses months of screening. Each trial placement is still the site's decision and the sponsor's decision; our role is to make that decision faster and better informed.
Strategy for product teams, from inside the center.
The same operating knowledge that gets a site trial-ready answers the questions commercial and medical affairs teams bring us: where to expand the treatment network, why adoption differs between centers, and where eligible patients are lost before referral.
Treatment network strategy
Market mapping and treatment-center prioritization, readiness and capability assessments, and activation planning, so investment goes where it will expand access fastest.
Treatment center adoption and performance
Product onboarding support, diagnosis of the operational and financial barriers at each center, financial viability modeling, and adoption and utilization insight.
Patient access and referral insight
Referral pathway mapping, community-to-treatment-center leakage analysis, workflow frameworks, and reimbursement, SOP, and training support for centers.
We know sites from the inside.
Inside-the-center perspective
Built by people who have operated cell therapy programs, not merely advised them.
Manufacturer and provider visibility
We understand both product-team priorities and treatment-center realities, because we work with both.
Cross-functional diagnosis
Clinical, operational, financial, and referral issues evaluated together, not in silos.
Strategy through execution
We identify the barrier, design the intervention, and support the implementation.
Tell us about your program.
Share your protocol's site requirements and target geographies, or the question your product team is working on, and we will come back with how we would approach it.